Yesterday, Gilead Sciences announced that Remdesivir, the lone drug approved for emergency coronavirus treatment by the FDA, will cost over $3,000 per five-day treatment, after receiving more than $70 million dollars in taxpayer funds to facilitate clinical trials. The price has drawn widespread criticism from health experts, and generic manufacturers are selling identical treatments at roughly six-hundred dollars per five-day treatment in at least two countries. Scott Perry however has remained silent.
That’s no surprise given that Congressman Perry has already voted to give big pharma companies, like Gilead, billions in tax breaks and voted against lowering the cost of prescription drugs last year.
Eugene DePasquale, Democratic candidate for Pennsylvania’s 10th Congressional District, issued the following statement in response to news reports on the announcement:
“For too long, drug companies, with the help of Washington politicians like my opponent Scott Perry, have exploited the American people, and forced them to pay unconscionable prices for the prescriptions they need,” said DePasquale. “It is for this very reason I have refused to take a dime from big Pharma, because while Congressman Perry happily accepts their campaign contributions in exchange for his silence, when I go to Washington I will hold them to account.”
Eugene has pledged to never take a dime from big Pharma in his run for Congress and as Pennsylvania’s Auditor General, issued a special report highlighting the sharp rise in the cost of prescription drugs for Pennsylvania families.